3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other solid neoplasm
1
NET
1
Endocrine
1
Conditions
Advanced Solid Tumors
1
Interventions
pembrolizumab
41
Injections
39
toripalimab
23
Nivolumab
22
Cisplatin
19
Pemetrexed
18
Carboplatin
18
Cyclophosphamide
17
Paclitaxel
14
Bevacizumab
14
fludarabine
12
Gemcitabine
11
tislelizumab
10
Ipilimumab
10
spartalizumab
9
Irinotecan
9
atezolizumab
8
Docetaxel
8
Oxaliplatin
7
Leucovorin
7
Fluorouracil
7
Capecitabine
6
sintilimab
5
Interleukin-2
5
Albumin-Bound Paclitaxel
5
130-nm albumin-bound paclitaxel
5
trifluridine tipiracil drug combination
4
sotorasib
4
pazopanib
4
palbociclib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Antiemetics
×
Other solid neoplasm
×
Clear all
NCT06242691
2026-06-05
MK-1200-002
Merck Sharp & Dohme LLC
Phase 1/2
Completed
13 enrolled
21 charts